Welcome to our dedicated page for CervoMed SEC filings (Ticker: CRVO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on CervoMed's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into CervoMed's regulatory disclosures and financial reporting.
CervoMed Inc. has completed enrollment in its Phase 2a clinical study of neflamapimod in nonfluent variant primary progressive aphasia (nfvPPA), a form of frontotemporal dementia with no approved treatments. The trial enrolled 25 participants on two oral dosing regimens over 24 weeks, followed by a 12‑week placebo‑controlled extension at leading U.S. academic centers.
Interim biomarker data from the study are scheduled to be presented at the 19th Clinical Trials on Alzheimer’s Disease (CTAD) conference in Boston on November 16–19, 2026, with initial clinical data expected in the first quarter of 2027. Recent preclinical work published in Nature Neuroscience shows that p38α inhibition, including with neflamapimod, reversed axonal transport deficits in tau‑mutation FTD models, supporting the drug’s mechanistic rationale. Neflamapimod holds U.S. FDA Orphan Drug Designation for FTD, providing development and exclusivity benefits if approved.
CervoMed Inc shareholders were updated when Morgan Stanley and Morgan Stanley Capital Services LLC amended their Schedule 13G filings to report reduced holdings. Morgan Stanley reports 0.1% of the class with 10,000 shared voting power and 12,550 shared dispositive power; Morgan Stanley Capital Services LLC reports 0.0%.
The filing states both entities "have ceased to be the beneficial owner of more than five percent of the class of securities." The amendment is signed by an authorized signatory and includes exhibits for a joint filing agreement and Item 7 subsidiary details.
CervoMed Inc. files a shelf registration to permit resale by selling stockholders of up to 10,081,131 shares of common stock, consisting of issued shares and shares issuable upon exercise of Pre-Funded Warrants, Series B Warrants and Series C Warrants issued in a June 11, 2026 private placement. The Company states it will not receive proceeds from resale by the selling stockholders but would receive cash proceeds if any Warrants are exercised for cash, and discloses recent financings including a 2,500,000-share Registered Offering that closed June 22, 2026 for gross proceeds of $10.0 million.
CervoMed Inc. Schedule 13G filing reports that CVI Investments, Inc. and Heights Capital Management, Inc. together beneficially hold 750,000 shares of CervoMed common stock, representing 5.5% of the class. The filing references 13,526,233 Shares outstanding as of completion of the offering per the Prospectus Supplement dated June 22, 2026. Heights Capital Management, Inc. is the investment manager to CVI Investments, Inc. and may be deemed to possess voting and dispositive power over the shares; both Reporting Persons disclaim beneficial ownership except for pecuniary interest. The submission is signed by Sarah Travis and includes a Limited Power of Attorney and a Joint Filing Agreement as exhibits.
CervoMed Inc. closed a registered direct offering of 2,500,000 shares of common stock at $4.00 per share, raising gross proceeds of $10 million. The transaction was priced at-the-market under Nasdaq rules, with H.C. Wainwright & Co. acting as exclusive placement agent.
The company plans to use the net proceeds for working capital and general corporate purposes. The shares were issued under an effective Form S-3 shelf registration statement using a final prospectus supplement and accompanying prospectus filed with the SEC.
CervoMed Inc. is offering 2,500,000 shares of common stock at an offering price of $4.00 per share pursuant to this prospectus supplement. Delivery is expected on or about June 22, 2026, with estimated net proceeds to the company of approximately $9.1 million.
The offering is being conducted on a best-efforts basis with H.C. Wainwright & Co. as exclusive placement agent and assumes sale of all shares. The prospectus supplement notes a public float of $32,126,620 based on 11,026,233 shares outstanding and 7,105,447 shares held by non-affiliates. Recent corporate items include a notice of allowance from the U.S. Patent and Trademark Office dated June 16, 2026 and a closed private placement on June 11, 2026 that generated approximately $10.5 million in gross proceeds.
CervoMed Inc. entered into definitive agreements for a registered direct offering of 2,500,000 shares of common stock at $4.00 per share, for aggregate gross proceeds of $10.0 million. The company plans to use the net proceeds for working capital and general corporate purposes.
H.C. Wainwright & Co. is acting as exclusive placement agent, receiving a 6.0% cash fee, a 1.0% management fee, specified expense reimbursements, and Placement Agent Warrants equal to 6.0% of the shares sold, exercisable at $5.00 per share. CervoMed agreed to a 30‑day lock‑up on most new equity issuances and a six‑month restriction on variable rate transactions, with customary exceptions. The new shares are being issued off an effective Form S‑3 shelf, while the Placement Agent Warrants and any pre‑funded warrants are being issued in a private placement with beneficial ownership limits of 4.99%, adjustable up to 9.99% after notice.
CervoMed Inc. reported that it received a notice of allowance from the United States Patent and Trademark Office for a new patent covering its drug candidate neflamapimod. The patent protects use of neflamapimod to treat dementia with Lewy bodies in patients without substantial Alzheimer’s disease-like tau pathology and is expected to provide intellectual property protection into 2042, strengthening long-term exclusivity for this indication.
Joshua S. Boger filed Amendment No. 2 to his Schedule 13D on CervoMed Inc., reporting beneficial ownership of 2,204,143 shares of common stock, or 19.99% of the outstanding shares, based on 11,026,233 shares of common stock outstanding.
His position includes shares held directly, through the JSB 2021 Trust and ASB 2021 Trust, as well as stock options and a limited amount of warrant shares constrained by a 19.99% maximum ownership limitation. The filing also reflects participation by the JSB 2021 Trust in a June 11, 2026 private placement of 955,414 units, each priced at $3.14 and including common stock plus Series B and Series C warrants.
CervoMed Inc. director-associated trusts participated in a significant private placement. On June 11, 2026, the Joshua S. Boger 2021 Trust purchased 955,414 units at $3.14 per unit in a private placement, each unit consisting of one share of common stock plus one Series B warrant and one Series C warrant.
The Series B warrants have a $3.32 exercise price and expire five years from issuance, while the Series C warrants have a $3.14 exercise price and expire one year from issuance. After these transactions, trusts for which Joshua S. Boger is sole trustee hold 1,600,117 and 195,748 common shares, respectively, though he disclaims beneficial ownership of these securities.